PicoCELA Inc. (NASDAQ:PCLA) Short Interest Down 19.2% in February

PicoCELA Inc. (NASDAQ:PCLA) saw a large decrease in short interest in February. As of February 27th, there was short interest totaling 10,866 shares, a decrease of 19.2% from the February 12th total of 13,443 shares. Based on an average daily trading volume, of 6,078 shares, the days-to-cover ratio is currently 1.8 days. Currently, 27.2% of the shares of the stock are sold short. Currently, 27.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 6,078 shares, the days-to-cover ratio is currently 1.8 days.

PicoCELA Stock Performance

PCLA opened at $2.25 on Friday. The business’s 50-day moving average price is $5.36 and its two-hundred day moving average price is $9.18. PicoCELA has a 1 year low of $2.25 and a 1 year high of $112.20. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.13 and a quick ratio of 1.57.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of PicoCELA in a report on Friday, January 9th. One analyst has rated the stock with a Sell rating, According to MarketBeat, PicoCELA has an average rating of “Sell”.

Institutional Trading of PicoCELA

An institutional investor recently bought a new position in PicoCELA stock. Jane Street Group LLC acquired a new stake in PicoCELA Inc. (NASDAQ:PCLA) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 172,132 shares of the company’s stock, valued at approximately $52,000. Jane Street Group LLC owned about 18.92% of PicoCELA as of its most recent SEC filing.

About PicoCELA

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.